ES3041723T3 - Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis - Google Patents

Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Info

Publication number
ES3041723T3
ES3041723T3 ES21709019T ES21709019T ES3041723T3 ES 3041723 T3 ES3041723 T3 ES 3041723T3 ES 21709019 T ES21709019 T ES 21709019T ES 21709019 T ES21709019 T ES 21709019T ES 3041723 T3 ES3041723 T3 ES 3041723T3
Authority
ES
Spain
Prior art keywords
human
treatment
als
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21709019T
Other languages
English (en)
Spanish (es)
Inventor
Gilbert Bensimon
Peter Nigel Leigh
Timothy Tree
Cecilia Garlanda
Massimo Locati
Janine Kirby
Pamela Shaw
Andrea Malaspina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Univ De Nimes
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sheffield
Kings College London
Queen Mary University of London
University of Sussex
Humanitas Mirasole SpA
Original Assignee
Centre Hospitalier Univ De Nimes
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sheffield
Kings College London
Queen Mary University of London
University of Sussex
Humanitas Mirasole SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ De Nimes, Assistance Publique Hopitaux de Paris APHP, Sorbonne Universite, Centre Hospitalier Universitaire de Nimes, University of Sheffield, Kings College London, Queen Mary University of London, University of Sussex, Humanitas Mirasole SpA filed Critical Centre Hospitalier Univ De Nimes
Application granted granted Critical
Publication of ES3041723T3 publication Critical patent/ES3041723T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES21709019T 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis Active ES3041723T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305241 2020-03-06
PCT/EP2021/055570 WO2021176044A1 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
ES3041723T3 true ES3041723T3 (en) 2025-11-14

Family

ID=71083549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21709019T Active ES3041723T3 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Country Status (8)

Country Link
US (2) US20230090069A1 (https=)
EP (2) EP4647123A3 (https=)
JP (1) JP7840267B2 (https=)
AU (1) AU2021230103A1 (https=)
CA (1) CA3166887A1 (https=)
ES (1) ES3041723T3 (https=)
TW (1) TWI894224B (https=)
WO (1) WO2021176044A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630035A1 (en) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Also Published As

Publication number Publication date
AU2021230103A1 (en) 2022-09-22
EP4114440C0 (en) 2025-06-25
US20230090069A1 (en) 2023-03-23
JP7840267B2 (ja) 2026-04-03
CA3166887A1 (en) 2021-09-10
EP4114440B1 (en) 2025-06-25
TW202146041A (zh) 2021-12-16
EP4647123A3 (en) 2025-12-24
JP2023516774A (ja) 2023-04-20
US20240335510A1 (en) 2024-10-10
EP4647123A2 (en) 2025-11-12
WO2021176044A1 (en) 2021-09-10
EP4114440A1 (en) 2023-01-11
TWI894224B (zh) 2025-08-21

Similar Documents

Publication Publication Date Title
De Benedetti et al. Efficacy and safety of emapalumab in macrophage activation syndrome
Chandran et al. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial
EP3443979B1 (en) Il-2 dosage regimen for treating systemic lupus erythematosus
US10293028B2 (en) Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
KR102201428B1 (ko) 암의 면역학적 치료에 유용한 생물학적 마커
US20240335510A1 (en) Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
Takeuchi et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
Mitroulis et al. Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities
ES2935834T3 (es) Métodos para tratar enfermedad de inmunodeficiencia
CN115515585A (zh) 用于治疗中性粒细胞减少症的方法
ES2455167T3 (es) Método de terapia combinada y formulación
ES3023044T3 (en) Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein
Tanaka et al. Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab
WO2021209080A2 (es) Péptido para el tratamiento del síndrome de la tormenta de citocinas
WO2019126384A1 (en) Effective il-12 dosing regimens
US20240238235A1 (en) Methods and compositions for treating pulmonary alveolar proteinosis related to mars mutations
Kobrynski LRBA (lipopolysaccharide-responsive and beige-like anchor protein) deficiency (OMIM# 614700)
Guo et al. Recurrent macrophage activation syndrome in patients with refractory systemic lupus erythematosus treated with emapalumab: a case report
Somech et al. Localized Juvenile Periodontitis
Zinngrebe et al. LUBAC Deficiencies
HK40003184B (en) Il-2 dosage regimen for treating systemic lupus erythematosus
Choi The Matricellular Protein CCN1 Regulates Colitis, Colitis-Associated Cancer, And Neutrophil Mobilization